Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS)
Diabetes, Obesity and Metabolism Jan 10, 2018
Terauchi Y, et al. - The long-term safety and efficacy of tofogliflozin as an add-on treatment to insulin were evaluated over 52 weeks. The authors revealed the safety and efficacy of tofogliflozin as an add-on to insulin therapy in type 2 diabetes mellitus patients. This served as a new therapeutic solution to diabetes management.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
